CLINICAL_TRIALS
trial_result
· 2013-11-01
Clinical Trial Update: Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine [Phase 2]
Summary
Phase 2 clinical trial evaluating treatment for iatrogenic weight gain and dyslipidemia caused by olanzapine in schizophrenia. The study was terminated and resu…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GW Research Ltd | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2013-11-01